

# Robert M Califf

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7291347/publications.pdf>

Version: 2024-02-01

244  
papers

25,964  
citations

14614

66  
h-index

6454

157  
g-index

257  
all docs

257  
docs citations

257  
times ranked

26196  
citing authors

#	ARTICLE	IF	CITATIONS
1	Importance of Social Determinants in Screening for Depression. <i>Journal of General Internal Medicine</i> , 2022, 37, 2736-2743.	1.3	10
2	Roadmap to 2030 for Drug Evaluation in Older Adults. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 210-223.	2.3	19
3	Biological and clinical correlates of the patient health questionnaire-9: exploratory cross-sectional analyses of the baseline health study. <i>BMJ Open</i> , 2022, 12, e054741.	0.8	3
4	Generating evidence for therapeutic effects: the need for well-conducted randomized trials. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	6
5	A call to action for new global approaches to cardiovascular disease drug solutions. <i>European Heart Journal</i> , 2021, 42, 1464-1475.	1.0	29
6	Avoiding the Coming Tsunami of Common, Chronic Disease. <i>Circulation</i> , 2021, 143, 1831-1834.	1.6	17
7	Mapping and quantification of the twitter footprint of cardiologists. <i>European Heart Journal Digital Health</i> , 2021, 2, 374-378.	0.7	5
8	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. <i>Circulation</i> , 2021, 144, 159-169.	1.6	18
9	Return of individual research results: What do participants prefer and expect?. <i>PLoS ONE</i> , 2021, 16, e0254153.	1.1	10
10	A holistic approach for suppression of COVID-19 spread in workplaces and universities. <i>PLoS ONE</i> , 2021, 16, e0254798.	1.1	13
11	Toward a Mobile Platform for Real-world Digital Measurement of Depression: User-Centered Design, Data Quality, and Behavioral and Clinical Modeling. <i>JMIR Mental Health</i> , 2021, 8, e27589.	1.7	29
12	Monitoring the Pediatric Clinical Trials Enterprise. <i>Pediatrics</i> , 2021, 148, e2021051589.	1.0	0
13	Life expectancy and voting patterns in the 2020 U.S. presidential election. <i>SSM - Population Health</i> , 2021, 15, 100840.	1.3	4
14	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e022485.	1.6	0
15	The Ecosystem to Support People with Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, , .	0.7	4
16	Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. <i>Contemporary Clinical Trials</i> , 2020, 88, 105775.	0.8	5
17	Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2014661.	2.8	3
18	Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006606.	0.9	12

#	ARTICLE	IF	CITATIONS
19	Randomized Trials Versus Common Sense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	1.2	50
20	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. Diabetes Care, 2020, 43, 2485-2492.	4.3	3
21	Rural-Urban Differences in Cardiovascular Mortality in the US, 1999-2017. JAMA - Journal of the American Medical Association, 2020, 323, 1852.	3.8	94
22	Reimagining What We Measure in Atherosclerosis's "a Phenotype Stack". Circulation Research, 2020, 126, 1146-1158.	2.0	8
23	The Project Baseline Health Study: a step towards a broader mission to map human health. Npj Digital Medicine, 2020, 3, 84.	5.7	38
24	Precision Health Analytics With Predictive Analytics and Implementation Research. Journal of the American College of Cardiology, 2020, 76, 306-320.	1.2	25
25	Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association. Circulation, 2020, 141, e615-e644.	1.6	168
26	Big Data in the Assessment of Pediatric Medication Safety. Pediatrics, 2020, 145, .	1.0	6
27	Understanding the use of observational and randomized data in cardiovascular medicine. European Heart Journal, 2020, 41, 2571-2578.	1.0	24
28	Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines. American Heart Journal, 2020, 226, 4-12.	1.2	6
29	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. Journal of the American College of Cardiology, 2019, 74, 1057-1068.	1.2	32
30	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older. JAMA Cardiology, 2019, 4, 846.	3.0	81
31	Representativeness of a Heart Failure Trial by Race and Sex. JACC: Heart Failure, 2019, 7, 980-992.	1.9	30
32	Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review. PLoS ONE, 2019, 14, e0219894.	1.1	10
33	Facilitating translational team science: The project leader model. Journal of Clinical and Translational Science, 2019, 3, 140-146.	0.3	8
34	Oral Fluoroquinolones. Journal of the American College of Cardiology, 2019, 74, 1451-1453.	1.2	2
35	Technology-Enabled Clinical Trials. Circulation, 2019, 140, 1426-1436.	1.6	59
36	High-quality evidence to inform clinical practice. Lancet, The, 2019, 394, 633-634.	6.3	10

#	ARTICLE	IF	CITATIONS
37	Consequences of Slow Progress Toward Pragmatism in Randomized Clinical Trials. <i>JAMA Cardiology</i> , 2019, 4, 1129.	3.0	5
38	Proposals to Lower Medication Costs—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 982.	3.8	0
39	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. <i>American Heart Journal</i> , 2019, 218, 110-122.	1.2	7
40	Employ Cybersecurity Techniques Against the Threat of Medical Misinformation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 207.	3.8	2
41	Consent for Research Participation in Practice. <i>American Journal of Bioethics</i> , 2019, 19, 19-21.	0.5	0
42	Filling in the Evidence About Sunscreen. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2077.	3.8	17
43	Lowering Cost and Increasing Access to Drugs Without Jeopardizing Innovation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1571.	3.8	21
44	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1069.	3.8	144
45	Reframing Global Variation in Heart Failure Trials. <i>JACC: Heart Failure</i> , 2019, 7, 347-349.	1.9	1
46	Digital clinical trials: creating a vision for the future. <i>Npj Digital Medicine</i> , 2019, 2, 126.	5.7	53
47	Balanced Dysfunction in the Healthcare Ecosystem Harms Patients. <i>Circulation</i> , 2019, 140, 1860-1864.	1.6	1
48	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
49	Differences in Health Outcomes between Men and Women: Biological, Behavioral, and Societal Factors. <i>Clinical Chemistry</i> , 2019, 65, 19-23.	1.5	9
50	Improving Clinical Outcomes in the Era of Information Ubiquity. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 7-12.	3.0	0
51	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005041.	0.9	23
52	Standardized classification and framework for reporting and interpreting medication non-adherence in clinical trials. <i>European Heart Journal</i> , 2019, 40, 2086-2088.	1.0	2
53	Stroke prevention in atrial fibrillation: re-defining "real-world data"™ within the broader data universe. <i>European Heart Journal</i> , 2018, 39, 2932-2941.	1.0	22
54	Biomarker definitions and their applications. <i>Experimental Biology and Medicine</i> , 2018, 243, 213-221.	1.1	722

#	ARTICLE	IF	CITATIONS
55	Improving Heart Failure Therapeutics Development in the United States. <i>Journal of the American College of Cardiology</i> , 2018, 71, 443-453.	1.2	40
56	Comparison of Observational Data and the ONTARGET Results for Telmisartan Treatment of Hypertension. <i>JAMA Internal Medicine</i> , 2018, 178, 63.	2.6	3
57	Providing Individual Research Results to Participantsâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2601.	3.8	2
58	Future of Personalized Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3301-3309.	1.2	28
59	Work and Cardiovascular Disease in China. <i>JAMA Network Open</i> , 2018, 1, e184815.	2.8	0
60	A Beginning to Principles of Ethical and Regulatory Oversight of Patient-Centered Research. <i>Annals of Internal Medicine</i> , 2018, 169, 579.	2.0	1
61	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	0.9	13
62	Large Clinical Trials and Registriesâ€”Clinical Research Institutes. , 2018, , 411-444.		0
63	Heart Failure With Preserved Ejection Fraction Expert Panel Report. <i>JACC: Heart Failure</i> , 2018, 6, 619-632.	1.9	103
64	Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. <i>American Journal of Cardiology</i> , 2018, 122, 1451-1458.	0.7	2
65	Individual risk prediction using data beyond the medical clinic. <i>Cmaj</i> , 2018, 190, E947-E948.	0.9	3
66	The future of humans as model organisms. <i>Science</i> , 2018, 361, 552-553.	6.0	31
67	Transforming Psychiatry into Data-Driven Medicine with Digital Measurement Tools. <i>Npj Digital Medicine</i> , 2018, 1, 37.	5.7	49
68	Expedited and facilitated drug evaluations and evidence of benefit and risk: The cup is half-full. <i>Clinical Trials</i> , 2018, 15, 235-239.	0.7	5
69	Return of Research Results to Study Participants. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 435.	3.8	49
70	Accelerating development of scientific evidence for medical products within the existing US regulatory framework. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 297-298.	21.5	50
71	Evaluating Evolving Technologies in a Time of Rapid Change. <i>JAMA Cardiology</i> , 2017, 2, 830.	3.0	1
72	Finding ideal blood pressure targets in ischaemic stroke: prospective insight or retrospective guesswork?. <i>European Heart Journal</i> , 2017, 38, 2836-2837.	1.0	1

#	ARTICLE	IF	CITATIONS
73	Warning About Shortcuts in Drug Development. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	2
74	Cosmetics, Regulations, and the Public Health. <i>JAMA Internal Medicine</i> , 2017, 177, 1080.	2.6	16
75	Pragmatic clinical trials: Emerging challenges and new roles for statisticians. <i>Clinical Trials</i> , 2016, 13, 471-477.	0.7	19
76	Transforming Evidence Generation to Support Health and Health Care Decisions. <i>New England Journal of Medicine</i> , 2016, 375, 2395-2400.	13.9	123
77	Resourcing Drug Development Commensurate With its Public Health Importance. <i>JACC Basic To Translational Science</i> , 2016, 1, 309-312.	1.9	4
78	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016, 1, 93-100.	2.7	1
79	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016, 171, 25-32.	1.2	11
80	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016, 102, 1036-1043.	1.2	36
81	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	1.6	127
82	Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 389-397.	1.1	14
83	Exploring the ethical and regulatory issues in pragmatic clinical trials. <i>Clinical Trials</i> , 2015, 12, 436-441.	0.7	153
84	Simultaneous Consideration of Multiple Candidate Protein Biomarkers for Long-Term Risk for Cardiovascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 168-177.	5.1	17
85	Ethical and regulatory issues of pragmatic cluster randomized trials in contemporary health systems. <i>Clinical Trials</i> , 2015, 12, 276-286.	0.7	43
86	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. <i>European Heart Journal</i> , 2015, 36, 288-296.	1.0	266
87	CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes. <i>Clinical and Translational Science</i> , 2015, 8, 623-631.	1.5	7
88	Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. <i>BMJ Open</i> , 2015, 5, e007901.	0.8	7
89	Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e001349.	1.6	12
90	Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function. <i>JACC: Heart Failure</i> , 2015, 3, 40-49.	1.9	35

#	ARTICLE	IF	CITATIONS
91	LCZ696: too good to be true?. <i>European Heart Journal</i> , 2015, 36, 410-412.	1.0	10
92	Methods and initial findings from the Durham Diabetes Coalition: Integrating geospatial health technology and community interventions to reduce death and disability. <i>Journal of Clinical and Translational Endocrinology</i> , 2015, 2, 26-36.	1.0	21
93	Translation of acute coronary syndrome therapies: From evidence to routine clinical practice. <i>American Heart Journal</i> , 2015, 169, 266-273.	1.2	14
94	Compliance with Results Reporting at ClinicalTrials.gov. <i>New England Journal of Medicine</i> , 2015, 372, 1031-1039.	13.9	319
95	The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015, 169, 743-750.	1.2	15
96	Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. <i>American Heart Journal</i> , 2015, 170, 117-122.	1.2	27
97	Cardiovascular Drug Development. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1567-1582.	1.2	168
98	Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Lancet, The</i> , 2015, 385, 2363-2370.	6.3	123
99	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015, 170, 290-297.e1.	1.2	57
100	Utility of Socioeconomic Status in Predicting 30-Day Outcomes After Heart Failure Hospitalization. <i>Circulation: Heart Failure</i> , 2015, 8, 473-480.	1.6	55
101	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 777-785.	1.9	19
102	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PProject of Ex-vivo Vein graft ENgineering via Transfection IV Trial. <i>American Heart Journal</i> , 2015, 169, 175-184.	1.2	23
103	Venous Thromboembolism and Cardiovascular Risk: Results from the NAVIGATOR Trial. <i>American Journal of Medicine</i> , 2015, 128, 297-302.	0.6	9
104	The Patient-Centered Outcomes Research Network. <i>North Carolina Medical Journal</i> , 2014, 75, 204-210.	0.1	35
105	Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. <i>Circulation: Heart Failure</i> , 2014, 7, 918-925.	1.6	42
106	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. <i>Circulation</i> , 2014, 130, 958-965.	1.6	41
107	Check It, Change It. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 828-834.	0.9	30
108	Large simple trials: really, it can't be that simple!. <i>European Heart Journal</i> , 2014, 35, 549-551.	1.0	5

#	ARTICLE	IF	CITATIONS
109	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 3377-3385.	1.0	154
110	Launching PCORnet, a national patient-centered clinical research network. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 578-582.	2.2	491
111	Clinical Trials in Peripheral Vascular Disease. <i>Circulation</i> , 2014, 130, 1812-1819.	1.6	40
112	Ethics and Regulatory Complexities for Pragmatic Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2381.	3.8	114
113	Commentary on Vickers. <i>Clinical Trials</i> , 2014, 11, 626-627.	0.7	2
114	Vein Graft Preservation Solutions, Patency, and Outcomes After Coronary Artery Bypass Graft Surgery. <i>JAMA Surgery</i> , 2014, 149, 798.	2.2	74
115	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	0.7	57
116	The Landscape of Clinical Trials in Nephrology: A Systematic Review of ClinicalTrials.gov. <i>American Journal of Kidney Diseases</i> , 2014, 63, 771-780.	2.1	118
117	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. <i>Heart Rhythm</i> , 2014, 11, 925-932.	0.3	52
118	Independent data monitoring committees: Preparing a path for the future. <i>American Heart Journal</i> , 2014, 168, 135-141.e1.	1.2	16
119	Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: Insights from the ClinicalTrials.gov registry. <i>American Heart Journal</i> , 2014, 168, 213-219.e1.	1.2	73
120	Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov. <i>American Heart Journal</i> , 2014, 167, 921-929.e2.	1.2	31
121	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 1873-1880.	1.0	145
122	Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction. <i>JACC: Heart Failure</i> , 2014, 2, 159-165.	1.9	91
123	Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. <i>Lancet, The</i> , 2014, 383, 1059-1066.	6.3	186
124	Factors Associated With Major Bleeding Events. <i>Journal of the American College of Cardiology</i> , 2014, 63, 891-900.	1.2	212
125	Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 840-846.	0.8	14
126	Patient-Centered Outcomes Composites. <i>Circulation</i> , 2014, 130, 1223-1224.	1.6	4



#	ARTICLE	IF	CITATIONS
127	Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial. <i>International Journal of Cardiology</i> , 2014, 176, 1126-1128.	0.8	11
128	Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery. <i>Circulation</i> , 2014, 130, 1445-1451.	1.6	181
129	Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. <i>Stroke</i> , 2014, 45, 1739-1747.	1.0	142
130	Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes—'Authors' reply. <i>Lancet</i> , The, 2014, 384, 1097-1098.	6.3	4
131	The new era of clinical research: Using data for multiple purposes. <i>American Heart Journal</i> , 2014, 168, 133-134.	1.2	2
132	Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. <i>Lancet</i> , The, 2014, 383, 2008-2017.	6.3	194
133	Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Circulation</i> , 2014, 130, 138-146.	1.6	345
134	Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 554-561.	1.5	37
135	Abstract 16866: Blood Pressure Control and Stroke or Bleeding Risk in Patients with Atrial Fibrillation: Results from the ROCKET AF Trial. <i>Circulation</i> , 2014, 130, .	1.6	0
136	Rescuing clinical trials in the United States and beyond: A call for action. <i>American Heart Journal</i> , 2013, 165, 837-847.	1.2	45
137	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 651-658.	1.2	181
138	Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States. <i>JACC: Heart Failure</i> , 2013, 1, 523-530.	1.9	22
139	Better Late Than Never. <i>JACC: Heart Failure</i> , 2013, 1, 112-114.	1.9	4
140	Forging Stronger Partnerships Between Academic Health Centers and Patient-Driven Organizations. <i>Academic Medicine</i> , 2013, 88, 1220-1224.	0.8	17
141	Randomized Clinical Trials — Removing Unnecessary Obstacles. <i>New England Journal of Medicine</i> , 2013, 369, 1061-1065.	13.9	103
142	Assessing Research Results in the Medical Literature. <i>JAMA Internal Medicine</i> , 2013, 173, 1053.	2.6	7
143	Geographic Health Information Systems: A Platform To Support The "Triple Aim"™. <i>Health Affairs</i> , 2013, 32, 1608-1615.	2.5	64
144	Portfolio of Clinical Research in Adult Cardiovascular Disease as Reflected in ClinicalTrials.gov. <i>Journal of the American Heart Association</i> , 2013, 2, e000009.	1.6	13

#	ARTICLE	IF	CITATIONS
145	Cycle Time Metrics for Multisite Clinical Trials in the United States. Therapeutic Innovation and Regulatory Science, 2013, 47, 152-160.	0.8	12
146	Embedding Cardiovascular Research Into Practice. JAMA - Journal of the American Medical Association, 2013, 310, 2037.	3.8	35
147	A comparison of phenotype definitions for diabetes mellitus. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, e319-e326.	2.2	96
148	Predictive Models in Heart Failure. Circulation: Heart Failure, 2013, 6, 877-878.	1.6	12
149	The Future of Cardiovascular Clinical Research. JAMA - Journal of the American Medical Association, 2012, 308, 1747.	3.8	24
150	Establishing a Framework for Improving the Quality of Clinical and Translational Research. Journal of Clinical Oncology, 2012, 30, 1725-1726.	0.8	6
151	A New Look at an Old Therapy. JAMA - Journal of the American Medical Association, 2012, 307, 1972.	3.8	9
152	In search of the efficient way to medical decisions: The case of acute heart failure syndrome. American Heart Journal, 2012, 164, 135-137.	1.2	1
153	Rationale for key elements of Sino-American collaboration in clinical research. Journal of Translational Medicine, 2012, 10, .	1.8	0
154	Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010. JAMA - Journal of the American Medical Association, 2012, 307, 1838.	3.8	403
155	Abstract 152: Predictors of Intracranial Hemorrhage Among Anticoagulated Patients with Atrial Fibrillation: Insights from the Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Stroke, 2012, 43, .	1.0	6
156	American Industry and the U.S. Cardiovascular Clinical Research Enterprise. Journal of the American College of Cardiology, 2011, 58, 677-680.	1.2	39
157	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 883-891.	13.9	8,006
158	The ClinicalTrials.gov Results Database " Update and Key Issues. New England Journal of Medicine, 2011, 364, 852-860.	13.9	628
159	A Historical Perspective on Clinical Trials Innovation and Leadership. JAMA - Journal of the American Medical Association, 2011, 305, 713.	3.8	58
160	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. Journal of Thrombosis and Thrombolysis, 2011, 32, 242-266.	1.0	2
161	Commentary on Anand et al.. Clinical Trials, 2011, 8, 724-725.	0.7	0
162	Reengineering the National Clinical and Translational Research Enterprise: The Strategic Plan of the National Clinical and Translational Science Awards Consortium. Academic Medicine, 2010, 85, 463-469.	0.8	65

#	ARTICLE	IF	CITATIONS
163	Linking Scientific Discovery and Better Health for the Nation: The First Three Years of the NIH's Clinical and Translational Science Awards. <i>Academic Medicine</i> , 2010, 85, 457-462.	0.8	52
164	Towards a new order in cardiovascular medicine: re-engineering through global collaboration. <i>European Heart Journal</i> , 2010, 31, 911-917.	1.0	10
165	An update on the IMPROVED Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. <i>American Heart Journal</i> , 2010, 159, 705-709.	1.2	82
166	Careers for Clinician Investigators. <i>Circulation</i> , 2009, 119, 2945-2950.	1.6	11
167	Scientific Evidence Underlying the ACC/AHA Clinical Practice Guidelines. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 831.	3.8	774
168	Rational use of medications: If Canada can't do it .... <i>Cmaj</i> , 2009, 181, 15-16.	0.9	3
169	A Virtuous Cycle to Improve Hypertension Outcomes at a National Level. <i>Hypertension</i> , 2009, 53, 105-107.	1.3	4
170	Clinical Research Sites—The Underappreciated Component of the Clinical Research System. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2025.	3.8	32
171	Traversing the Valley of Death: A Guide to Assessing Prospects for Translational Success. <i>Science Translational Medicine</i> , 2009, 1, 10cm9.	5.8	77
172	Ethical and Scientific Implications of the Globalization of Clinical Research. <i>New England Journal of Medicine</i> , 2009, 360, 816-823.	13.9	628
173	Key issues for global cardiovascular medicine. <i>Lancet, The</i> , 2009, 374, 508-510.	6.3	7
174	The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 782-786.	0.9	5
175	Sensible approaches for reducing clinical trial costs. <i>Clinical Trials</i> , 2008, 5, 75-84.	0.7	153
176	Considerations of net present value in policy making regarding diagnostic and therapeutic technologies. <i>American Heart Journal</i> , 2008, 156, 879-885.	1.2	15
177	Rationale and design of IMPROVE-IT (IMPROVED Reduction of Outcomes: Vytorin Efficacy International) outcomes in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2008, 156, 826-832.	1.2	280
178	Organizational Improvements to Enhance Modern Clinical Epidemiology. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2300.	3.8	14
179	Sensible guidelines for the conduct of large randomized trials. <i>Clinical Trials</i> , 2008, 5, 38-39.	0.7	51
180	Response to The J-Point Revisited. <i>Hypertension</i> , 2008, 51, .	1.3	0

#	ARTICLE	IF	CITATIONS
181	Analyses of Cancer Data from Three Ezetimibe Trials. <i>New England Journal of Medicine</i> , 2008, 359, 1357-1366.	13.9	230
182	Curbing The Cardiovascular Disease Epidemic: Aligning Industry, Government, Payers, And Academics. <i>Health Affairs</i> , 2007, 26, 62-74.	2.5	30
183	Is There a Price to Pay for Short-Term Savings in the Clinical Development of New Pharmaceutical Products?. <i>Drug Information Journal</i> , 2007, 41, 491-499.	0.5	1
184	Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 5-16.	0.9	17
185	Clinical trials bureaucracy: unintended consequences of well-intentioned policy. <i>Clinical Trials</i> , 2006, 3, 496-502.	0.7	78
186	Recent Trends in the Care of Patients With Non- $\sigma$ ST-Segment Elevation Acute Coronary Syndromes. <i>Archives of Internal Medicine</i> , 2006, 166, 2027.	4.3	153
187	Translating clinical trials into practice. <i>Texas Heart Institute Journal</i> , 2006, 33, 192-6.	0.1	2
188	Prognostic/Clinical Prediction Models: Using Observational Data to Estimate Prognosis: An Example Using a Coronary Artery Disease Registry. , 2005, , 287-314.		0
189	A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non- $\sigma$ ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2005, 149, S91-S99.	1.2	10
190	Defining The Balance Of Risk And Benefit In The Era Of Genomics And Proteomics. <i>Health Affairs</i> , 2004, 23, 77-87.	2.5	26
191	Benefit the patient, manage the risk: a system goal. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 269-276.	0.9	12
192	A time of accelerated change in academic cardiovascular medicine. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1957-1965.	1.2	1
193	Task Force 2: Investigator Participation in Clinical Research. <i>Circulation</i> , 2004, 110, 2517-2524.	1.6	1
194	Red Blood Cell S-Nitrosohemoglobin Deficiency in Pulmonary Arterial Hypertension.. <i>Blood</i> , 2004, 104, 1583-1583.	0.6	0
195	Toward protecting the safety of participants in clinical trials. <i>Contemporary Clinical Trials</i> , 2003, 24, 256-271.	2.0	56
196	Principles From Clinical Trials Relevant to Clinical Practice: Part II. <i>Circulation</i> , 2002, 106, 1172-1175.	1.6	36
197	Principles From Clinical Trials Relevant to Clinical Practice: Part I. <i>Circulation</i> , 2002, 106, 1015-1021.	1.6	98
198	Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure. <i>Circulation</i> , 2002, 106, 920-926.	1.6	582

#	ARTICLE	IF	CITATIONS
199	Integrating quality into the cycle of therapeutic development. Journal of the American College of Cardiology, 2002, 40, 1895-1901.	1.2	145
200	Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?. Statistics in Medicine, 2002, 21, 2889-2897.	0.8	1
201	Introduction: Redefining acute coronary syndrome care in the era of aggressive revascularization. Clinical Cardiology, 2002, 25, 1-1.	0.7	0
202	Matching resources to treatment decisions for patients with acute coronary syndromes. Clinical Cardiology, 2002, 25, 2-8.	0.7	1
203	Statistical approaches and policies for the operations of Data and Safety Monitoring Committees. American Heart Journal, 2001, 141, 301-305.	1.2	13
204	Using observational data to estimate prognosis: an example using a coronary artery disease registry. Statistics in Medicine, 2001, 20, 2505-2532.	0.8	22
205	MEDICINE: Placebo-Controls in Short-Term Clinical Trials of Hypertension. Science, 2001, 292, 2013-2015.	6.0	38
206	Patients Who Want their Family and Physician to Make Resuscitation Decisions for Them: Observations from SUPPORT and HELP. Journal of the American Geriatrics Society, 2000, 48, S84-90.	1.3	179
207	Physician Understanding Of Patient Resuscitation Preferences: Insights and Clinical Implications. Journal of the American Geriatrics Society, 2000, 48, S44-51.	1.3	110
208	Canadian-American Differences in the Management of Acute Coronary Syndromes in the GUSTO IIb Trial. Circulation, 2000, 102, 1375-1381.	1.6	53
209	Cigarette Smoking. Circulation, 2000, 102, 1340-1341.	1.6	4
210	Early Percutaneous Coronary Intervention, Platelet Inhibition With Eptifibatide, and Clinical Outcomes in Patients With Acute Coronary Syndromes. Circulation, 2000, 101, 751-757.	1.6	104
211	Predictors of Mortality and Mortality From Cardiac Causes in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial and Registry. Circulation, 2000, 101, 2682-2689.	1.6	119
212	Cost-Effectiveness of Platelet Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Non-ST-Elevation Acute Coronary Syndromes. Circulation, 2000, 101, 366-371.	1.6	106
213	Prediction of 1-Year Survival After Thrombolysis for Acute Myocardial Infarction in the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial. Circulation, 2000, 101, 2231-2238.	1.6	133
214	Evaluating the Potential Economic Attractiveness of New Therapies in Patients with Non-ST Elevation Acute Coronary Syndrome. Pharmacoeconomics, 2000, 17, 263-272.	1.7	12
215	Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Non-ST-Elevation Acute Coronary Syndromes. Circulation, 1999, 100, 2045-2048.	1.6	281
216	Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab. Circulation, 1999, 99, 1951-1958.	1.6	154

#	ARTICLE	IF	CITATIONS
217	Relationship Between Delay in Performing Direct Coronary Angioplasty and Early Clinical Outcome in Patients With Acute Myocardial Infarction. <i>Circulation</i> , 1999, 100, 14-20.	1.6	532
218	Cardiogenic Shock in Patients With Acute Ischemic Syndromes With and Without ST-Segment Elevation. <i>Circulation</i> , 1999, 100, 2067-2073.	1.6	225
219	The GUSTO Trials. <i>Journal of Interventional Cardiology</i> , 1999, 12, 13-31.	0.5	1
220	New Agents, New Trials, New Solutions. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 5, S151-S159.	1.0	0
221	Atrioventricular and Intraventricular Conduction Disorders in Acute Myocardial Infarction: A Reappraisal in the Thrombolytic Era. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998, 21, 2651-2663.	0.5	44
222	Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients. <i>Circulation</i> , 1998, 97, 1702-1707.	1.6	163
223	Outcomes of Diabetic Patients Following Acute Myocardial Infarction: A Review of the Major Thrombolytic Trials. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1997, 4, 100-111.	3.1	3
224	Surrogate and Physician Understanding of Patients' Preferences for Living Permanently in a Nursing Home. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 818-824.	1.3	160
225	Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective. <i>Journal of Thrombosis and Thrombolysis</i> , 1997, 4, 415-423.	1.0	3
226	Impact of an Aggressive Invasive Catheterization and Revascularization Strategy on Mortality in Patients With Cardiogenic Shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Trial. <i>Circulation</i> , 1997, 96, 122-127.	1.6	177
227	Relationship Between Diabetes Mellitus and Long-term Survival After Coronary Bypass and Angioplasty. <i>Circulation</i> , 1997, 96, 2551-2556.	1.6	225
228	Identifying patient risk: The basis for rational discharge planning after acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 1996, 3, 107-115.	1.0	6
229	Operator-Specific Outcomes. <i>Circulation</i> , 1996, 93, 403-406.	1.6	27
230	Economic Assessment of Platelet Glycoprotein IIb/IIIa Inhibition for Prevention of Ischemic Complications of High-Risk Coronary Angioplasty. <i>Circulation</i> , 1996, 94, 629-635.	1.6	119
231	A Multicenter, Randomized Trial of Coronary Angioplasty Versus Directional Atherectomy for Patients With Saphenous Vein Bypass Graft Lesions. <i>Circulation</i> , 1995, 91, 1966-1974.	1.6	169
232	Atenolol reduced ischemia-related events in asymptomatic ischemia. <i>ACP Journal Club</i> , 1995, 122, 32.	0.1	0
233	Use of Medical Resources and Quality of Life after Acute Myocardial Infarction in Canada and the United States. <i>New England Journal of Medicine</i> , 1994, 331, 1130-1135.	13.9	322
234	Early ischemia after thrombolytic therapy for a first myocardial infarction was associated with increased total cardiac events and emergency revascularization. <i>ACP Journal Club</i> , 1993, 119, 82.	0.1	0

#	ARTICLE	IF	CITATIONS
235	Thrombolytic Therapy for Acute Myocardial Infarction. <i>Drugs</i> , 1992, 44, 293-325.	4.9	145
236	Thrombolytic therapy for myocardial infarction: A perspective of clinical trialists. <i>Clinical Cardiology</i> , 1992, 15, 143-144.	0.7	0
237	Parenteral Anticoagulation with the Heparinoid Lomoparan (Org 10172) in Patients with Heparin Induced Thrombocytopenia and Thrombosis. <i>Thrombosis and Haemostasis</i> , 1992, 67, 292-296.	1.8	49
238	Intravenous Heparin, Thrombolytics, and Medical Marketing. <i>Journal of Interventional Cardiology</i> , 1991, 4, 1-4.	0.5	6
239	Correlation between Baseline Plasminogen Activator Inhibitor Levels and Clinical Outcome during Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 1991, 65, 275-279.	1.8	51
240	Brachial approach to emergency cardiac catheterization during thrombolytic therapy for acute Myocardial Infarction. <i>Catheterization and Cardiovascular Diagnosis</i> , 1990, 20, 221-226.	0.7	5
241	Current Management of Mitral Valve Incompetence Associated with Coronary Artery Disease. <i>Journal of Cardiac Surgery</i> , 1989, 4, 25-42.	0.3	20
242	Regression modelling strategies for improved prognostic prediction. <i>Statistics in Medicine</i> , 1984, 3, 143-152.	0.8	1,486
243	Tying clinical research to patient care by use of an observational database. <i>Statistics in Medicine</i> , 1984, 3, 375-384.	0.8	69
244	A View from Academia. , 0, , 67-76.		0